Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection.
OBJECTIVE
To evaluate the clinical efficacy of FK-506 on suppressing high-risk cornea transplantation rejection.


METHODS
In a randomized controlled clinical trial, 56 eyes of 56 patients with high-risk keratoplasty (including total corneal transplantation TCT, total corneal transplantation with circular lamellar sclera CST, vascularization corneal transplantation and corneal retransplantation) were divided into the experimental group and the control group (each with 28 eyes). The experimental group was treated by FK-506 eyedrops (0.5 mg/ml) and TobraDex eyedrops, compared with the control group that was treated by 1% CsA eyedrops and TobraDex eyedrops. In the average 8.1-month follow-up period, the visual acuity, graft transparent duration and Rejection Index (RI) of grafts were observed.


RESULTS
In the follow-up period, the graft rejection rate of the experimental and the control group was 63.6% and 95.2% respectively (chi2 = 4.72, P < 0.05) with significant difference.


CONCLUSIONS
The local application of FK-506 suppressed effectively the graft rejection of corneal transplantation of the patients at high risk.
Wang
Minhua
M
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
Lin
Yuesheng
Y
Chen
Jiaqi
J
Liu
Yongming
Y
Xie
Hanping
H
Ye
Chengtian
C
D000328:Adult; D000368:Aged; D016039:Corneal Transplantation; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D012307:Risk Factors; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016559:Tacrolimus